<DOC>
	<DOCNO>NCT02397486</DOCNO>
	<brief_summary>The purpose study determine whether pentoxifylline vitamin E effective prevention radiotherapy- induced toxicity head neck cancer patient treat concurrent chemoradiotherapy .</brief_summary>
	<brief_title>The Impact Pentoxifylline Vitamin E Radiotherapy-induced Toxicity Head &amp; Neck Cancer Patients</brief_title>
	<detailed_description>This randomize control prospective study pentoxifylline vitamin E give daily basis throughout period concurrent chemoradiotherapy patient carcinoma head neck . All patient follow 90 day since first day treatment . The incidence severity adverse event assess accord National Cancer Institute Common Terminology Criteria Adverse Events version 4 .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Adult patient Measurable disease Patients squamous cell carcinoma head neck eligible treatment concurrent chemo radiotherapy Able understand willing sign write informed consent document Pregnant lactate woman , since image do setting . Patients treat vitamin E and/ pentoxifylline indication Patients recent cerebral and/or retinal hemorrhage Patients previously exhibit intolerance pentoxifylline methylxanthines caffeine , theophylline , theobromine . Patients treat oral anticoagulant . Absolute neutrophil count ≤1.5×109/L Platelets ≤100×109/L AST ≥ 2.5 X institutional upper limit normal ( ULN ) Serum creatinine ≥ 1.5 mg % males &amp; 1.4 mg % females Serum bilirubin ≥ 1.5X institutional upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>